Stock Analysis Report

Header cover image

Executive Summary

ZIM Laboratories Limited manufactures, markets, and sells formulation drugs and pre formulation ingredients in India and internationally.

Snowflake Analysis

Adequate balance sheet with questionable track record.

Share Price & News

How has ZIM Laboratories's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 541400's share price has been volatile over the past 3 months.

Market Performance

7 Day Return




IN Pharmaceuticals


IN Market

1 Year Return




IN Pharmaceuticals


IN Market

Return vs Industry: 541400 underperformed the Indian Pharmaceuticals industry which returned 43.7% over the past year.

Return vs Market: 541400 underperformed the Indian Market which returned 1.4% over the past year.

Shareholder returns

7 Day14.2%6.9%-0.07%
30 Day36.0%10.4%3.3%
90 Day44.8%16.9%18.2%
1 Year-20.5%-20.8%45.8%43.7%3.3%1.4%
3 Yearn/a23.2%19.6%-1.6%-6.2%
5 Yearn/a1.1%-2.5%25.0%15.6%

Price Volatility Vs. Market

How volatile is ZIM Laboratories's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is ZIM Laboratories undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 541400 (₹91.15) is trading above our estimate of fair value (₹6.59)

Significantly Below Fair Value: 541400 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 541400 is poor value based on its PE Ratio (44.9x) compared to the IN Pharmaceuticals industry average (21.5x).

PE vs Market: 541400 is poor value based on its PE Ratio (44.9x) compared to the Indian market (13x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 541400's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 541400 is good value based on its PB Ratio (1x) compared to the IN Pharmaceuticals industry average (1.9x).

Next Steps

Future Growth

How is ZIM Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ZIM Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has ZIM Laboratories performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 541400 has high quality earnings.

Growing Profit Margin: 541400's current net profit margins (1.2%) are lower than last year (4.6%).

Past Earnings Growth Analysis

Earnings Trend: 541400 has become profitable over the past 5 years, growing earnings by 24.6% per year.

Accelerating Growth: 541400's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 541400 had negative earnings growth (-78.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (15.9%).

Return on Equity

High ROE: 541400's Return on Equity (2.1%) is considered low.

Next Steps

Financial Health

How is ZIM Laboratories's financial position?

Financial Position Analysis

Short Term Liabilities: 541400's short term assets (₹1.8B) exceed its short term liabilities (₹1.4B).

Long Term Liabilities: 541400's short term assets (₹1.8B) exceed its long term liabilities (₹280.5M).

Debt to Equity History and Analysis

Debt Level: 541400's debt to equity ratio (50.1%) is considered high.

Reducing Debt: 541400's debt to equity ratio has reduced from 98.7% to 50.1% over the past 5 years.

Debt Coverage: 541400's debt is well covered by operating cash flow (28.4%).

Interest Coverage: 541400's interest payments on its debt are not well covered by EBIT (0.6x coverage).

Balance Sheet

Next Steps


What is ZIM Laboratories's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 541400's dividend (0.55%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.67%).

High Dividend: 541400's dividend (0.55%) is low compared to the top 25% of dividend payers in the Indian market (2.78%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 541400 has been paying a dividend for less than 10 years.

Growing Dividend: 541400 has only been paying a dividend for 2 years, and since then payments have not increased.

Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (24.6%), 541400's dividend payments are well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Anwar Daud

no data


Dr. Anwar Siraj Daud, M.Pharm has been the Managing Director of Zim Laboratories Limited since April 01, 2009. He also serves as Chairman of the Zim Laboratories Limited and has been its Executive Director ...

CEO Compensation Analysis

Compensation vs Market: Anwar's total compensation ($USD0.00) is below average for companies of similar size in the Indian market ($USD49.49K).

Compensation vs Earnings: Insufficient data to compare Anwar's compensation with company performance.

Board Members

Anwar Daud
Executive Chairman & MDno datano data27.43%
₹ 397.2m
Riazahmed Kamal
Director of Administration & Executive Director22.58yrsno data0.021%
₹ 303.1k
Niraj Dhadiwal
Director of Business Development & Executive Director6.75yrsno data0.46%
₹ 6.7m
Zulfiquar Kamal
Director of Finance & Executive Director7.83yrsno data2.45%
₹ 35.5m
Prakash Sapkal
Director of Operations & Whole-Time Executive Director6.75yrsno data0.47%
₹ 6.7m
Naresh Gaikwad
Independent Director10.42yrsno data0.0025%
₹ 35.6k
Zakir Vali
Chairman Emeritusno data₹600.00k17.54%
₹ 254.0m
Rahul Deshpande
Independent Nominee Directorno datano datano data
Suprakash Chakravarty
Independent Director7.83yrsno datano data
V. Parashar
Independent Director12.08yrsno datano data
Padmakar Joshi
Independent Director2.92yrsno datano data
Kavita Loya
Independent Director2.92yrsno datano data


Average Tenure


Average Age

Experienced Board: 541400's board of directors are considered experienced (7.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

ZIM Laboratories Limited's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: ZIM Laboratories Limited
  • Ticker: 541400
  • Exchange: BSE
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.448b
  • Shares outstanding: 16.24m
  • Website:


  • ZIM Laboratories Limited
  • Sadoday Gyan
  • Ground Floor
  • Nagpur
  • Maharashtra
  • 440 013
  • India


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
541400BSE (Mumbai Stock Exchange)YesEquity SharesININRJun 2018


ZIM Laboratories Limited manufactures, markets, and sells formulation drugs and pre formulation ingredients in India and internationally. The company offers technology-based drug delivery solutions and non ...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 12:59
End of Day Share Price2020/08/03 00:00
Annual Earnings2020/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.